PFS (days) | OS (days) | |||||||
---|---|---|---|---|---|---|---|---|
QL1101a | Bevacizumabb | HR (95% CI)c | Pd | QL1101a | Bevacizumabb | HR (95% CI)c | Pd | |
Age (years) | ||||||||
< 65 | 169 | 147 | 0.9985 (0.8014–1.244) | < 0.001 | Undefined | Undefined | 0.9792 (0.6854–1.399 | 0.0134 |
≥ 65 | 131 | 137 | 1.288 (0.8777–1.890) | 1.673 | 459 | 508 | 1.150 (0.6985–1.894) | 0.3025 |
Gender | ||||||||
Male | 150 | 134 | 1.065 (0.825–1.374) | 0.2321 | 459 | 566 | 1.161 (0.8203–1.643) | 0.7084 |
Female | 141 | 147 | 1.093 (0.8203–1.456) | 0.3687 | Undefined | Undefined | 0.8216 (0.4839–1.395) | 0.5290 |
Smoking history | ||||||||
Never | 150 | 168 | 1.130 (0.8807–1.450) | 0.9231 | Undefined | Undefined | 1.032 (0.6695–1.592) | 0.0209 |
Ever | 170 | 133 | 0.9533 (0.6372–1.426) | 0.0541 | 459 | 497 | 1.004 (0.6791–1.484) | < 0.001 |
Still | 130 | 121 | 0.9171 (0.5900–1.426) | 0.1479 | Undefined | 396.5 | 0.6473 (0.3583–1.169) | 2.078 |
Pathology | ||||||||
Wild type | 150 | 144 | 1.058 (0.8448–1.325) | 0.2409 | Undefined | 566 | 1.003 (0.7329–1.374) | 0.0275 |
EGFR mutation | 142.5 | 138 | 1.091 (0.7627–1.561) | 0.2286 | Undefined | Undefined | 1.260 (0.5921–2.682) | 0.3602 |
Tumor history | ||||||||
Yes | 146 | 175 | 1.602 (0.7613–3.371) | 1.541 | Undefined | 513 | 0.3735 (0.1200–1.163) | 2.888 |
No | 145 | 140 | 1.033 (0.8479–1.259) | 0.8161 | Undefined | Undefined | 1.085 (0.8038–1.465) | 0.2838 |
ECOG | ||||||||
0 | 158 | 132 | 0.7639 (0.5121–1.139) | 1.744 | Undefined | Undefined | 1.281 (0.6763–2.426) | 0.5772 |
1 | 144 | 154 | 1.174 (0.9451–1.459) | 2.105 | Undefined | Undefined | 0.9589 (0.6922–1.328) | 0.0638 |
aBevacizumab biosimilar sourced from Qilu Pharmaceutical Co., Ltd, China. bBevacizumab sourced from Roche China. cHazard Ratio (95% CI of ratio. dChi square value using Mantel-Cox test.